# Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

> **NCT04233021** · PHASE2 · COMPLETED · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 57 (actual)

## Conditions studied

- Non Small Cell Lung Cancer Metastatic
- Leptomeningeal Metastasis
- Brain Metastases
- EGFR Activating Mutation

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT04233021
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-16
- **Primary completion:** 2023-03-15
- **Final completion:** 2024-12-27
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233021, "Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04233021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*